Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoeaBITNER, M; KATTENHORN, J; HATFIELD, C et al.International journal of clinical practice (Esher). 2004, Vol 58, Num 4, pp 340-345, issn 1368-5031, 6 p.Article

Lumiracoxib (Prexige®): a new selective cox-2 inhibitorMYSLER, E.International journal of clinical practice (Esher). 2004, Vol 58, Num 6, pp 606-611, issn 1368-5031, 6 p.Article

Preclinical pharmacology of lumiracoxib : a novel selective inhibitor of cyclooxygenase-2ESSER, Ronald; BERRY, Carol; QUADROS, Elizabeth et al.British journal of pharmacology. 2005, Vol 144, Num 4, pp 538-550, issn 0007-1188, 13 p.Article

Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch modelESSER, Ronald E; MISERENDINO-MOLTENI, Rocca; SHARR, Michele et al.European journal of pharmaceutical sciences. 2005, Vol 25, Num 1, pp 25-30, issn 0928-0987, 6 p.Article

Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test : A combination analysis studyCAPUANO, Alessandro; DE CORATO, Alice; TREGLIA, Mariangela et al.European journal of pharmacology. 2009, Vol 605, Num 1-3, pp 57-62, issn 0014-2999, 6 p.Article

Global gastrointestinal safety profile of etoricoxib and lumiracoxib : COX-2 inhibition in gastroenterology and rheumatology: current challenges and perspectives for the futureYUHONG YUAN; HUNT, Richard H.Current pharmaceutical design. 2007, Vol 13, Num 22, pp 2237-2247, issn 1381-6128, 11 p.Article

Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental painZELENAKAS, K; FRICKE, J. R; JAYAWARDENE, S et al.International journal of clinical practice (Esher). 2004, Vol 58, Num 3, pp 251-256, issn 1368-5031, 6 p.Article

Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental painKELLSTEIN, D; OTT, D; JAYAWARDENE, S et al.International journal of clinical practice (Esher). 2004, Vol 58, Num 3, pp 244-250, issn 1368-5031, 7 p.Article

Clinical pharmacology of lumiracoxib : A selective cyclo-oxygenase-2 inhibitorRORDORF, Christiane M; CHOI, Les; MARSHALL, Paul et al.Clinical pharmacokinetics. 2005, Vol 44, Num 12, pp 1247-1266, issn 0312-5963, 20 p.Article

Lumiracoxib. CommentariesLYSENG-WILLIAMSON, Katherine A; CURRAN, Monique P; PATRIGNANI, Paola et al.Drugs (Basel). 2004, Vol 64, Num 19, pp 2237-2248, issn 0012-6667, 12 p.Article

Pharmacokinetics and metabolism of lumiracoxib in healthy male subjectsMANGOLD, James B; GU, Helen; RODRIGUEZ, Lolita C et al.Drug metabolism and disposition. 2004, Vol 32, Num 5, pp 566-571, issn 0090-9556, 6 p.Article

Efficacy of the newest COX-2 selective inhibitors in rheumatic disease : COX-2 inhibition in gastroenterology and rheumatology: current challenges and perspectives for the futureBARAF, Herbert S. B.Current pharmaceutical design. 2007, Vol 13, Num 22, pp 2228-2236, issn 1381-6128, 9 p.Article

Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the ratFOX, Alyson; MEDHURST, Stephen; COURADE, Jean-Philippe et al.Pain (Amsterdam). 2004, Vol 107, Num 1-2, pp 33-40, issn 0304-3959, 8 p.Article

Therapeutic Arthritis Research and Gastrointestinal Event Trial of lumiracoxib: study design and patient demographicsHAWKEY, C. J; FARKOUH, M; GITTON, X et al.Alimentary pharmacology & therapeutics. 2004, Vol 20, Num 1, pp 51-63, issn 0269-2813, 13 p.Article

Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritisMACKENZIE, Isla S; LI WEI; MACDONALD, Thomas M et al.European journal of clinical pharmacology. 2013, Vol 69, Num 2, pp 133-141, issn 0031-6970, 9 p.Article

Peripheral and spinal mechanisms of antinociceptive action of lumiracoxibLOZANO-CUENCA, Jair; CASTANEDA-HERNANDEZ, Gilberto; GRANADOS-SOTO, Vinicio et al.European journal of pharmacology. 2005, Vol 513, Num 1-2, pp 81-91, issn 0014-2999, 11 p.Article

Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee : A 13-week, randomized, double-blind comparison with celecoxib and placeboSHELDON, Eric; BEAULIEU, André; PASTER, Zorba et al.Clinical therapeutics. 2005, Vol 27, Num 1, pp 64-77, issn 0149-2918, 14 p.Article

Lumiracoxib : hépatites et retraits du marché = Lumiracoxib and hepatitis : market withdrawalLa Revue Prescrire. 2008, Vol 28, Num 291, pp 27-27, issn 0247-7750, 1 p.Article

Pharmacokinetics of Lumiracoxib in plasma and synovial fluidSCOTT, Graham; RORDORF, Christiane; REYNOLDS, Christine et al.Clinical pharmacokinetics. 2004, Vol 43, Num 7, pp 467-478, issn 0312-5963, 12 p.Article

Adverse cardiovascular effects of the coxibsDOGND, Jean-Michel; SUPURAN, Claudiu T; PRATICO, Domenico et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 7, pp 2251-2257, issn 0022-2623, 7 p.Article

The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplastyCHAN, V. W. S; CLARK, A. J; DAVIS, J. C et al.Acta anaesthesiologica scandinavica. 2005, Vol 49, Num 10, pp 1491-1500, issn 0001-5172, 10 p.Article

Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritisHAWKEY, Christopher C; SVOBODA, Petr; FIEDOROWICZ-FABRYCY, Irena F et al.Journal of rheumatology. 2004, Vol 31, Num 9, pp 1804-1810, issn 0315-162X, 7 p.Article

Structure―toxicity relationship and structure―activity relationship study of 2-phenylaminophenylacetic acid derived compoundsYI YUN PANG; WEE KIANG YEO; KEP YONG LOH et al.Food and chemical toxicology. 2014, Vol 71, pp 207-216, issn 0278-6915, 10 p.Article

Liquid chromatographic determination of lumiracoxib in pharmaceutical formulationsOLIVEIRA, Paulo R; BERNARDI, Larissa S; MENDES, Cassiana et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 51, Num 3, pp 728-732, issn 0731-7085, 5 p.Article

Long-term efficacy and safety of lumiracoxib 100 mg : an open-label extension of a 13-week randomized controlled trial in patients with primary osteoarthritis of the kneeSHELDON, E. A; BEAULIEU, A; PASTER, Z et al.Clinical and experimental rheumatology (Testo stampato). 2008, Vol 26, Num 4, pp 611-619, issn 0392-856X, 9 p.Article